Bio-Rad Laboratories, Inc.
BIO
$305.56
-$0.99-0.32%
NYSE
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 2.56B | 2.55B | 2.54B | 2.57B | 2.58B |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 2.56B | 2.55B | 2.54B | 2.57B | 2.58B |
| Cost of Revenue | 1.22B | 1.20B | 1.18B | 1.19B | 1.18B |
| Gross Profit | 1.34B | 1.35B | 1.36B | 1.38B | 1.40B |
| SG&A Expenses | 807.06M | 802.36M | 793.06M | 810.06M | 813.22M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 2.30B | 2.29B | 2.26B | 2.29B | 2.27B |
| Operating Income | 262.43M | 260.43M | 281.33M | 276.13M | 313.12M |
| Income Before Tax | -842.62M | 450.08M | -2.75B | -2.34B | -1.01B |
| Income Tax Expenses | -166.72M | 130.89M | -586.12M | -498.32M | -226.54M |
| Earnings from Continuing Operations | -675.90 | 319.20 | -2.16K | -1.84K | -778.67 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -675.90M | 319.20M | -2.16B | -1.84B | -778.67M |
| EBIT | 262.43M | 260.43M | 281.33M | 276.13M | 313.12M |
| EBITDA | 424.53M | 417.23M | 433.93M | 427.73M | 462.72M |
| EPS Basic | -24.30 | 11.77 | -76.17 | -65.00 | -27.28 |
| Normalized Basic EPS | 6.81 | 6.67 | 7.18 | 6.96 | 7.78 |
| EPS Diluted | -24.31 | 11.73 | -76.20 | -65.04 | -27.34 |
| Normalized Diluted EPS | 6.81 | 6.66 | 7.18 | 6.96 | 7.77 |
| Average Basic Shares Outstanding | 110.09M | 111.11M | 112.28M | 112.86M | 113.65M |
| Average Diluted Shares Outstanding | 110.10M | 111.17M | 112.33M | 112.91M | 113.73M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |